Medicenna Therapeutics Corp. (TSE:MDNA – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of C$0.43 and traded as high as C$0.45. Medicenna Therapeutics shares last traded at C$0.44, with a volume of 11,564 shares changing hands.
Medicenna Therapeutics Price Performance
The company has a debt-to-equity ratio of 6.22, a quick ratio of 4.65 and a current ratio of 1.25. The company’s 50 day moving average price is C$0.43 and its 200-day moving average price is C$0.54. The company has a market cap of C$40.61 million, a price-to-earnings ratio of -2.00 and a beta of 2.49.
Medicenna Therapeutics Company Profile
Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.
Further Reading
- Five stocks we like better than Medicenna Therapeutics
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
